Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. LexaGene Holdings (LXG) has closed the second tranche of its private placement to Meridian LGH Holdings. DALLAS, Dec. 14, 2022 /CNW/ - Meridian Veterinary Capital, LLC (" Meridian "), a Texas limited liability company, announced today that it has filed an early warning report in respect of the. Dr. Regan commented, "The Company originally pursued repricing Meridian . While logged in and authenticated, you will not be asked to solve any complicated Recaptcha V2 challenges. Meridian LGH Holdings is a Dallas, Texas-based subsidiary of Meridian Veterinary Capital LLC. The first tranche consisted of 13,115,725 units priced at C$0.35 per unit (approximately US$0.27 per unit) for gross proceeds of C$4,590,503.75 (approximately US$3,541,245.75), bringing the total investment to nearly $6.5 million. LexaGene announces that it it has issued a 12% secured convertible note (the Note) to Meridian LGH Holdings 2, LLC. LexaGene Holdings ( OTCQB:LXXGF) has filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code. Toggle navigation OPEN GOV US Meridian LGH Holdings is a Dallas, Texas-based subsidiary of Meridian Veterinary Capital LLC. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors. We are sorry, but your computer or network may be sending automated queries. 2022-02-08 | TSXV:LXG.H | Press Release | Lexagene Holdings Inc Accelerate is an in-depth exploration of the science, ethos and implications of near-future transportation methods. All our content is produced independently by our experienced and qualified teams of news journalists. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately two hours. LexaGene Holdings (LXG) has closed the second tranche of its strategic private placement to Meridian LGH Holdings. Provides Update on Biopharma Sector, LexaGene Says MiQLab System Detects Mycoplasma at Minute Levels, Gets "Additional Interest" from BioPharma Customers, LEXAGENE HOLDINGS INC. : Q3 2023 Earnings Release, LexaGene Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022, LexaGene Gains as Engaged by BioPharma Firm in Second Feasibility Study; Cancels Plan to Reprice Meridian's Warrants, Lexagene Holdings Inc. Brief: Up 21% Early Friday As BioPharma Engages it in Second Feasibility Study; LXG Cancels Plans to Reprice Meridian's Warrants, LexaGene Successfully Completes Statement of Work for BioPharma Company, LexaGene Holdings Inc. announced that it has received $1.6 million in funding from Meridian LGH Holdings 2, LLC, LexaGene Says Large Biopharma Co Engages It in Statement of Work to Expedite Technology Validation, LexaGene Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022, LexaGene Rises 23% as Says Got Signed Quote from Large Biopharma Company to Buy a MiQLab System, LexaGene Says Received Signed Quote from Large Biopharma Company to Buy a MiQLab System, LexaGene Holdings Inc. Receives Signed Quote from Large Biopharma Company to Purchase A MiQLab System, LexaGene's MiQLab System Generates Leptospira Results in 30 minutes Using Isothermal Chemistry, LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 Minutes Using Isothermal Chemistry, LexaGene Says U of Penn's School of Veterinary Medicine to Evaluate New Gastrointestinal Panel With MiQLab System, Lexagene Holdings Inc. Reduces Time-To-Result by 35%, LexaGene Holdings Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022, LexaGene Holdings Completes Multi-Center Validation Study Using MiQLab System for Diagnosing Urinary Tract Infections, LexaGene Holdings Inc. Completes Multi-Center Validation Study Using MiQLab System for Diagnosing Urinary Tract Infections, LEXAGENE HOLDINGS INC. : FY 2022 Earnings Release, LexaGene Holdings Inc. Schedule Your Appointment. . AI Can Write, But Is It Any Good at Picking Stocks? Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Announces MiQLab System Sale to Veterinary Hospital in Wisconsin. An early warning report relating to these transactions will be filed on the System for Electronic Document Analysis and Review ("SEDAR") under the Issuer's profile and can be viewed at www.sedar.com. The securities referred in this news release have not been registered under the U.S. Securities Act, or any U.S. state securities laws, and such securities may not be offered or sold within the United States, or to or for the account or benefit of any U.S. person or any person in the United States, absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements. Company Bankruptcy Information for Lexagene Holdings Inc. This should have a meaningful impact on this aspect of veterinary care.. The company and the investor intend that the investment will occur by way of non-brokered private placement anticipated to close in two tranches. About LexaGene Holdings Inc. LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other . Assuming the conversion of the entire US$1,300,000principal amount outstanding under the Note (and assuming no accrued and unpaid interest on the Note), Meridian would, indirectly, own and exercise control over an additional 7,647,059 Common Shares, representing approximately 5.22% of the Issuer's issued and outstanding Common Shares (on a post-conversion basis). Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets. Lancaster General Hospital. Meridian LGH Holdings, LLC (trading name, 2022-01-20 - ) Agent Name Curtis R. Boisfontaine Jr Agent Address 3811 Turtle Creek Blvd., Suite 875, Dallas, TX, 75219-4419, USA Directors / Officers. Copyright Proactive Group Holdings Inc, 2023. The Bizapedia Pro API grants programmatic access to all the search forms and features you find on our site. All rights reserved. Upon closing of both tranches of the private placement, the investor will hold approximately 13.41 per cent of the issued and outstanding common shares of the company. Each unit is comprised of one share of Lexagene and one warrant, with each warrant entitling the holder to purchase one common share of the company for a period of 36 months at a price of C$0.45. LexaGene Holdings (TSXV:LXG) closes second tranche of Lexagene Holdings Inc. investor Meridian LGH Holdings LLC has agreed to make an investment in Lexagene for a total of $6,475,000 (Canadian) (approximately $4,995,000 (U.S.)). BEVERLY, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., ( OTCQB: LXXGF; TSX-V: LXG) ("LexaGene" or the "Company"), a molecular diagnostics company that has commercialized an. 10/24/2022 EDT *: *: * Interest on the note will be convertible at the market price of the shares on the TSXV at the time the interest is due and payable, subject to TSXV approval. The first tranche consisted of 13,115,725 units priced at C$0.35 per unit (approximately US$0.27 per unit) for gross proceeds of C$4,590,503.75 (approximately US$3,541,245.75), bringing the total investment to nearly $6.5 million. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that youve provided to them or that theyve collected from your use of their services. How May We Help You? 1 MarketScreener is worth more than 1000 Influencers! Cloud growth expectations for Microsoft, Amazon and Google seem doable, BRICS countries exploring gold-backed currency, potentially challenging US IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial. The Company acquires majority or controlling interests in companies involved in electronic commerce, electronic communication, and electronic business services. 04/25/2022: Sale of three MiQLabs to corporate veterinary Reference Lab. Closing of the Private Placement is subject to final TSX Venture Exchange approval. LexaGene Holdings Inc (TSX-V:LXG, OTCQB:LXXGF) said that Meridian LGH Holdings LLC has agreed to make an investment in LexaGene for a total of C$6,475,000 (approximately US$4,995,000). This website uses cookies so that we can provide you with the best user experience possible. Data delayed 15 minutes unless otherwise indicated. We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. All Rights Reserved - Proactive North America Inc., Proactive Investors LLC. Meridian Capital Group: Home An initial amount of US$400,000 was funded by Meridian Holdings II on November 1, 2022, and an additional US$500,000 and US$400,000 was funded on November 18, 2022 and December 9, 2022, respectively. LexaGene Holdings Proposes to Amend Warrants Terms Proactive has always been a forward looking and enthusiastic technology adopter. This should have a meaningful impact on this aspect of veterinary care. LexaGene provides an update on the Companys efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics. The company said it intends to use the proceeds of the private placement towards purchasing inventory for manufacturing more MiQLabSystems, supporting sales, marketing, and continued R&D. Upon closing of both tranches, the investor will hold approximately 13.41% of the issued and outstanding common shares of the company. Accelerate is an in-depth exploration of the science, ethos and implications of near-future transportation methods. LexaGene announces that it intends to amend the exercise price of certain common share purchase warrants. LexaGene Closes Secured Convertible Note Transaction To protect our site, we cannot process your request right now. This should have a meaningful impact on this aspect of veterinary care., Dr. Jack Regan, LexaGenes CEO and Founder, stated, Im thrilled to have Meridian LGH Holdings supporting LexaGenes mission to change the way animals are diagnosed and treated.. Meridian Veterinary Capital, Llc Announces Filing of Early Warning Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. This site is protected by reCAPTCHA and the Google. Meridian Holdings - Overview, News & Competitors | ZoomInfo.com LexaGene 2022 accomplishments : r/Lexagene Located between First and Second Avenues, the site features 47 feet of frontage along 44th Street with 100 feet of depth and allows for . Securities Act), any common shares of the Company acquired by, issued or issuable to, or otherwise owned by the Investor which are ineligible for immediate resale by the Investor to the public without volume limitations pursuant to Rule 144(b)(i) under the U.S. Securities Act (collectively, the Registrable Securities); and (b) piggyback registration rights that will allow the Investor to include Registrable Securities in any public offering of equity securities initiated by the Company (other than those public offerings pursuant to registration statements on Forms S-4 or S-8 under the U.S. Securities Act) or by any of the Companys other shareholders that have registration rights. person have the respective meanings ascribed to them in Regulation S under the U.S. Securities Act. All rights reserved. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that youve provided to them or that theyve collected from your use of their services. Market Indices, Commodities and Regulatory News Headlines copyright Morningstar. In addition, on November 1, 2022, the Issuer issued, to Meridian Holdings II, on a private placement basis, a senior convertible note (the "Note") for an aggregate principal amount of up to US$1,600,000 and bearing interest at a rate of 12% per annum (or 16% in the event of a default).
Clinical Trial Cost By Phase, Articles M